TRADING UPDATES: HSBC announces redemption of US dollar securities
Thu, 15th Apr 2021 19:37
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
HSBC Holdings PLC - London-based bank - Announces the redemption of its USD2.00 billion 6.875% perpetual subordinated contingent convertible securities. The redemption price will be USD1,000 per USD1,000 of the securities together with any accrued but unpaid interest.
RHI Magnesita NV - Vienna, Austria-headquartered supplier of refractory products - Notes appointment of Non-Executive Director Janet Ashdown as an independent non-executive director of Stolt-Nielsen Ltd, listed on the Oslo Bors.
Thu, 15th Apr 2021 19:37
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
HSBC Holdings PLC - London-based bank - Announces the redemption of its USD2.00 billion 6.875% perpetual subordinated contingent convertible securities. The redemption price will be USD1,000 per USD1,000 of the securities together with any accrued but unpaid interest.
RHI Magnesita NV - Vienna, Austria-headquartered supplier of refractory products - Notes appointment of Non-Executive Director Janet Ashdown as an independent non-executive director of Stolt-Nielsen Ltd, listed on the Oslo Bors.
Blue Star Capital PLC - investment company with a focus on esports, payments, technology and its applications within media and gaming - Says investee Dynasty eSports Pte Ltd achieved its first monthly profit on an operating basis in January. Says Dynasty expects to shortly conclude a round of fundraising in which it is
UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost
Wed, 23rd Dec 2020 19:50
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Polarean Imaging PLC - medical imaging products developer - Says US Food & Drug Administration approves company s new drug application. FDA acceptance for the filing of Polarean s NDA represents another important step forward for the Company s platform. If approved, Polarean s drug-device technology could provide a new diagnostic option for patients with pulmonary disease, Chief Executive Officer Richard Hullihen says. Polarean adds that Chief Operating Officer Ken West plans to retire as employee of company but to stay involved as a consultant before transitioning to non-executive role.